XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase.

[1]  M. Gould,et al.  Inhibition of type I and type II geranylgeranyl-protein transferases by the monoterpene perillyl alcohol in NIH3T3 cells. , 1997, Biochemical pharmacology.

[2]  D. Vigushin,et al.  Identification and characterization of limonene metabolites in patients with advanced cancer by liquid chromatography/mass spectrometry. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[3]  Y. Matsuzawa,et al.  Inhibition of cell growth of human hepatoma cell line (HepG2) by a farnesyl protein transferase inhibitor: A preferential suppression of ras farnesylation , 1996, International journal of cancer.

[4]  M. Barbacid,et al.  Development of highly potent inhibitors of Ras farnesyltransferase possessing cellular and in vivo activity. , 1996, Journal of medicinal chemistry.

[5]  W. R. Bishop,et al.  Novel Tricyclic Inhibitors of Farnesyl Protein Transferase , 1995, The Journal of Biological Chemistry.

[6]  N. Rosen,et al.  A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.

[7]  M. Barbacid,et al.  Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. , 1995, Oncogene.

[8]  Min Han,et al.  Ras farnesyltransferase inhibitors suppress the phenotype resulting from an activated ras mutation in Caenorhabditis elegans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Jirtle,et al.  Induction of apoptosis in liver tumors by the monoterpene perillyl alcohol. , 1995, Cancer research.

[10]  Sally J. Leevers,et al.  Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane , 1994, Nature.

[11]  R. Coombes,et al.  Effectiveness of combined limonene and 4-hydroxyandrostenedione in the treatment of NMU-induced rat mammary tumours. , 1994, British Journal of Cancer.

[12]  N. Kohl,et al.  Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic , 1994, Cell.

[13]  J. Avruch,et al.  Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation. , 1994, The Journal of biological chemistry.

[14]  C. Marshall,et al.  MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. , 1994, Current opinion in genetics & development.

[15]  A. Levinson,et al.  Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.

[16]  R. Coombes,et al.  Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. , 1992, British Journal of Cancer.

[17]  R. Jirtle,et al.  Modulation of insulin-like growth factor-II/mannose 6-phosphate receptors and transforming growth factor-beta 1 during liver regeneration. , 1991, The Journal of biological chemistry.

[18]  R. Grand,et al.  The biochemistry of ras p21. , 1991, The Biochemical journal.

[19]  Samuel Hellman,et al.  Important advances in oncology , 1991 .

[20]  D. Rifkin,et al.  Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  F. McCormick.  The world according to GAP. , 1990, Oncogene.

[22]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[23]  C. Marshall,et al.  All ras proteins are polyisoprenylated but only some are palmitoylated , 1989, Cell.

[24]  A. Ogura,et al.  Sarcoma viruses carrying ras oncogenes induce differentiation-associated properties in a neuronal cell line , 1985, Nature.

[25]  D. Bar-Sagi,et al.  Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation , 1985, Cell.

[26]  Mark R. Smith,et al.  Requirement for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells , 1985, Nature.

[27]  M. Wigler,et al.  Genetic analysis of yeast RAS1 and RAS2 genes , 1984, Cell.

[28]  M N Gould,et al.  Inhibition of DMBA-induced mammary cancer by the monoterpene d-limonene. , 1984, Carcinogenesis.

[29]  R. Coombes,et al.  Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer , 1998, Cancer Chemotherapy and Pharmacology.

[30]  S. Kornfeld.  Structure and function of the mannose 6-phosphate/insulinlike growth factor II receptors. , 1992, Annual review of biochemistry.